Optimal Treatment of Zollinger-Ellison Syndrome and Related Conditions in Elderly Patients

Drugs and Aging

Volumn 20, Issue 14, 2003, Pages 1019-1034

  Tomassetti, Paola ^a   Salomone, Teresa ^a   Migliori, Marina ^a   Campana, Davide ^a   Corinaldesi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CIMETIDINE; CISPLATIN; CYANOCOBALAMIN; DACARBAZINE; DOXORUBICIN; ESOMEPRAZOLE; ETOPOSIDE; FAMOTIDINE; FLUOROURACIL; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ARTICLE; ARTIFICIAL EMBOLISM; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CARCINOID; CARDIOVASCULAR DISEASE; CLINICAL EXAMINATION; DRUG EFFICACY; FLU LIKE SYNDROME; GASTRINOMA; GASTROINTESTINAL TOXICITY; HELICOBACTER PYLORI; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH SURGERY; TACHYPHYLAXIS; TREATMENT INDICATION; ZOLLINGER ELLISON SYNDROME;

AGED; CARCINOID TUMOR; GERIATRICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PROTON PUMPS; ZOLLINGER-ELLISON SYNDROME;

EID: 0348109328     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320140-00002     Document Type: Article

References (143)

1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 1955. CA Cancer J Clin 1989; 39: 231-47
2. Norton JA, Jensen RT. Multiple endocrine neoplasia. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publisher, 1997: 1723-29
3. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 1994; 97: 436-44
4. Mignon M, Cadiot G, Rigaud D, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia type 1. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management (Frontiers of Gastrointestinal Research; vol. 23). Basel: S. Karger AG, 1995: 342-59
5. Zollinger RM, Ayres HP. The Zollinger-Ellison syndrome. In: Nyhus LM, Wastell C, Donahue PE, editors. Surgery of the esophagus, stomach and small intestine. 4th ed. London: Little Brown & Company, 1987: 491-513
6. Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973; 65: 140-65
7. Ellison EC, Wilson SD. The Zollinger-Ellison syndrome: reappraisal and evaluation of 260 registered cases. Ann Surg 1964; 160: 512-30
8. Stage JG, Stadil F. The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl 1979; 53: 79-91
9. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 379-411
10. Yalow RS, Berson SA. Size and charge distinctions between endogenous human plasma gastrin in peripheral blood and heptadecapeptide gastrins. Gastroenterology 1970; 58: 609-15
11. Walsh JH. Gastrointestinal hormones. In: Johnson LR, editor. Physiology of the gastrointestinal tract. 2nd ed. New York: Raven Press, 1987: 182
12. Feldman M, Walsh JH, Wong HC, et al. Role of gastrin heptadecapeptide in the acid secretory response to amino acids in man. J Clin Invest 1978; 61: 308-13
13. Creutzfeldt W, Arnold R, Creutzfeldt C, et al. Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Hum Pathol 1975; 6: 47-76
14. Dockray GJ, Walsh JH. Amino terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients. Gastroenterology 1975; 68: 222-30
15. Rehfeld JF, Stadil F. Gel filtration studies on immunoreactive gastrin in serum from Zollinger-Ellison patients. Gut 1973; 14: 369-73
16. Walsh JH, Grossman MI. Gastrin (first of two parts). N Engl J Med 1975; 292: 1324-34
17. Walsh JH, Grossman MI. Gastrin (second of two parts). N Engl J Med 1975; 292: 1377-84
18. Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In: Go VLW, Brooks FA, DiMagno EP, Gardner JD, Lebenthal E, Scheele GA, editors. The exocrine pancreas: biology, pathobiology and disease. New York: Raven Press, 1986: 727-44
19. Johnson LR. New aspects of the trophic action of gastrointestinal hormones. Gastroenterology 1977; 72: 788-92
20. Dockray GJ, Gregory RA. Gastrin. In: Schultz SG, Makhlouf GM, Raurer BB, editors. Handbook of physiology. Bethesda: American Physiological Society, 1989: 311
21. Jensen RT, Gardner JD. Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. In: Zakim D, Dannenberg AJ, editors. Peptic ulcer disease and other acid-related disorder. New York: Accademic Research Associates, 1991: 117-246
22. Qureshi W, Rashid S. Zollinger-Ellison syndrome: improved treatment options for this complex disorder. Postgrad Med 1998; 104: 155-4
23. Rindi G, Luinetti O, Cornaggia M. et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006
24. Solcia E, Fiocca R, Villani L, et al. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19 Suppl. 1: S1-7
25. Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-72
26. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002; 123: 68-85
27. Bordi C, Azzoni C, Ferraro G, et al. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol 2000; 114: 419-25
28. Lehy T, Cadiot G, Mignon M, et al. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-9
29. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-88
30. Brandi ML, Aurbach GD, Fitzpatrick LA, et al. Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type 1. N Engl J Med 1986; 314: 1287-93
31. Solcia E, Rindi G, Larosa S, et al. Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microsc Res Tech 2000; 48: 339-48
32. Bordi C, Falchetti A, Azzoni C, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 1997; 21: 1075-82
33. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-30
34. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-49
35. Durieux S, Liote F, Timsit MA, et al. [Bone metastases in epidural invasion of gastrinoma]. Rev Rhum Ed Fr 1994; 61: 453-5
36. Maton PN. Gastrinoma and other hypergastrinemic syndrome. In: Walsh JH, Dockray GJ, editors. Gut peptides. New York: Raven Press, 1994: 675-700
37. Pederson RT, Haidak DJ, Ferris RA, et al. Osteoblastic bone metastasis in Zollinger-Ellison syndrome. Radiology 1976; 118: 63-4
38. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998; 16: 1040-53
39. Park HM, Gudkese DB, Clark SA, et al. Skeletal metastasis from gastrinoma: an uncommon manifestation of pancreatic endocrine tumor. Clin Nucl Med 1986; 11: 799-800
40. Barton JC, Hirschowitz BI, Maton PN, et al. Bone metastases in malignant gastrinoma. Gastroenterology 1986; 91: 1179-85
41. Ruszniewski P, Girard F, Benamouzig R, et al. Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. Gut 1988; 29: 838-42
42. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80: 189-222
43. Frucht H, Howard JM, Stark HA, et al. Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome. Am J Med 1989; 87: 528-36
44. Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: a prospective study. Ann Intern Med 1989; 111: 713-22
45. Fox PS, Hofmann JW, Wilson SD, et al. Surgical management of the Zollinger-Ellison syndrome. Surg Clin North Am 1974; 54: 395-407
46. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000; 118: 696-704
47. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97: 827-36
48. Jensen RT, Gardner JD, Raufman JP, et al. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 1983; 98: 59-75
49. Vinayek R, Howard JM, Maton PN, et al. Famotidine in the therapy of gastric hypersecretory states. Am J Med 1986; 81: 49-59
50. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983; 84: 108-13
51. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610
52. Jensen RT, Collen MJ, McArthur KE, et al. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. Am J Med 1984; 77: 90-105
53. McCarthy DM. Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states. Gastroenterology 1978; 74: 453-8
54. Howard JM, Chremos AN, Collen MJ, et al. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985; 88: 1026-33
55. Jensen RT. Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1984; 29: 363-6
56. Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94: 294-9
57. Vezzadini P, Tomassetti P, Toni R. Omeprazole in the medical treatment of Zollinger-Ellison syndrome. Curr Ther Res 1984; 35: 772-6
58. Thomson AB. Are the orally administered proton pump inhibitors equivalent?: a comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-93
59. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40: 52-62
60. Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40: 145-50
61. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related. Drugs 2002; 62 (10): 1503-38
62. Paul G, Ramdani A. Mignon M, et al. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal]. Gastroenterol Clin Biol 1994; 18: 695-701
63. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001; 15: 1795-806
64. Dobrilla G, Capurso L. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. Recenti Prog Med 2000; 91: 191-210
65. Gremse DA. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother 2001; 2: 1663-70
66. Bown RL. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Int J Clin Pract 2002; 56: 132-9
67. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82
68. Cheer SM, Prakash A, Faulds D, et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33
69. Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 725-42
70. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001; 61: 2327-56
71. Metz MD, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management (Frontiers of Gastrointestinal Research; vol. 23). Basel: S. Karger AG, 1995: 240-57
72. Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17: 468-80
73. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991; 36: 394-404
74. Bardram L, Stadil F. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl 1989; 166: 95-100
75. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther 1988; 2: 13-32
76. McArthur KE, Collen MJ, Maton PN, et al. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 1985; 88: 939-44
77. McTavish D, Buckley MM, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138-70
78. Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature 1981; 290: 159-61
79. Andersson T, Bergstrand R, Cederberg C, et al. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991; 101: 943-7
80. Termanini B, Gibril F, Stewart CA, et al. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 61-71
81. Metz DC, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 245-56
82. Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 507-22
83. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-508
84. Stadil F, Stage JG. The Zollinger-Ellison syndrome. Clin Endocrinol Metab 1979; 8: 433-46
85. Jansen JB, Lundborg P, Baak LC, et al. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 1988; 29: 75-80
86. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome: current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200-9
87. Maton PN, Lack EE, Collen MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99: 943-50
88. Wormsley KG. Risks of therapeutic achlorhydria. Scand J Gastroenterol 1988; 23 Suppl. 153: 35-51
89. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104: 422-30
90. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000; 30: 29-33
91. Metz DC. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000; 62: 73-81
92. Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 2001; 96: 3274-80
93. Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med 2002; 30: S356-61
94. White CM, Kalus J, Quercia R, et al. Esomeprazole capsule contents suspended in water can be efficiently delivered through nasogastric and gastrostomy tubes. Am J Gastroenterol 2002; 97 (9): S18-9
95. Sostek MB, Chen Y, Skammer W, et al. Esomeprazole: nasogastric tube, administration of the contents of an opened capsule suspended in water compared with oral administrationin healthy volunteers. Am J Gastroenterol 2002; 97 (9): S23
96. Weber HC, Venzon DJ, Jensen RT, et al. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology 1997; 112: 84-91
97. Watanabe T, Matsushima Y, Nakase H, et al. Effects of Helicobacter pylori infection on Zollinger-Ellison syndrome. J Gastroenterol 2000; 35: 735-41
98. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001; 15: 87-103
99. Ellison EC, O'Dorisio TM, Sparks J, et al. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas. Surgery 1986; 100: 437-44
100. Dunne MJ, Elton R, Fletcher T, et al. Sandostatin and gastroenteropancreatic endocrine tumors-therapeutics characteristics. In: O'Dorisio TM, editor. Sandostatin in the treatment of GEP endocrine tumors. Berlin Heidelberg: Springer-Verlag, 1989: 93-113
101. Ruszniewski P, Laucournet H, Elouaer-Blanc L, et al. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 1988; 3: 145-52
102. Bordi C, Azzoni C, Pilato FP, et al. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regul Pept 1993; 47: 307-18
103. Ruszniewski P, Ramdani A, Cadiot G, et al. Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 1993; 23: 296-301
104. Wood SM, Kraenzlin ME, Adrian TE, et al. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses. Gut 1985; 26: 438-44
105. Souquet JC, Sassolas G, Forichon J, et al. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987; 59: 1654-60
106. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 Suppl. 1: 84-91
107. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93: 1468-71
108. Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14: 557-60
109. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-8
110. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000; 12: 368-77
111. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-43
112. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phel-Tyr3-octreotide. Eur J Nucl Med 2001; 28: 426-34
113. Annibale B, De Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994; 8: 87-93
114. Cadiot G, Lehy T, Bonfils S. Action of somatostatin analogue (SMS 201-995) on the growth-promoting effect resulting from sustained achlorhydria in rat gastric mucosa, with special reference to endocrine cell behaviour. Eur J Clin Invest 1988; 18: 360-8
115. Modlin IM, Kumar R, Nangia A, et al. Gastrin-dependent inhibitory effects of octreotide on the genesis of gastric ECLomas. Surgery 1992; 112: 1048-56
116. Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343: 551-4
117. Hirschowitz BI. Clinical course of nonsurgically treated Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management (Frontiers of Gastrointestinal Research; vol. 23). Basel: S, Karger AG, 1995: 360-71
118. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-44
119. Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220: 320-8
120. Thompson NW, Bondeson AG, Bondeson L, et al. The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery 1989; 106: 1081-5
121. Fraker DL, Norton JA, Saeed ZA, et al. A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery 1988; 104: 1054-63
122. Mignon M, Ruszniewski P, Podevin P, et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 1993; 17: 489-97
123. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease: results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243: 495-500
124. Thompson NW. Surgical treatment of the endocrine pancreas and Zollinger-Ellison syndrome in the MEN 1 syndrome. Henry Ford Hosp Med J 1992; 40: 195-8
125. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 1993; 17: 455-62
126. Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med 1995; 238: 269-80
127. Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002; 386: 558-69
128. Arnold R, Frank M. Systemic chemotherapy for endocrine tunors of the pancreas. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management (Frontiers of Gastrointestinal Research; Vol. 23). Basel: S. Karger AG. 1995: 431-38
129. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997; 15: 2420-31
130. Murray-Lyon IM, Eddleston AL. Williams R, et al. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 1968; II: 895-8
131. Broder LE, Carter SK. Pancreatic islet cell carcinoma: II. results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79: 108-18
132. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189-94
133. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987; 14: 343-53
134. Kessinger A, Lemon HM, Foley JF. The glucagonoma syndrome and its management. J Surg Oncol 1977; 9: 419-24
135. Kelsen D, Fiore J, Heelan R, et al. Phase II trial of etoposide in APUD tumors. Cancer Treat Rep 1987; 71: 305-7
136. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-7
137. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62 Suppl. 1: 73-8
138. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94: 1326-34
139. Pisegna JR, Slimak GG, Doppman JL, et al. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 1993; 105: 1179-83
140. Eriksson B, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. In: Mignon M, Jensen RT. editors. Endocrine tumors of the pancreas: recent advances in research and management (Frontiers of Gastrointestinal Research: Vol. 23). Basel: S. Karger AG, 1995: 451-60
141. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 1998; 10: 58-65
142. Carrasco CH, Chuang VP, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 1983; 149: 79-83
143. Repetto L, Venturino A, Fratino L, et al. Geriatric oncology, a clinical approach to the older patient with cancer. Eur J Cancer 2003; 39: 870-80